Home › Compare › FITSF vs JNJ

FITSF vs JNJ: Dividend Comparison 2026

FITSF yields 2000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FITSF wins by $4.879226400974806e+39M in total portfolio value
10 years
FITSF
FITSF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full FITSF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — FITSF vs JNJ

📍 FITSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFITSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FITSF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
FITSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FITSF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, FITSF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FITSF + JNJ for your $10,000?

FITSF: 50%JNJ: 50%
100% JNJ50/50100% FITSF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FITSF
No analyst data
Altman Z
-179.0
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FITSF buys
0
JNJ buys
0
No recent congressional trades found for FITSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFITSFJNJ
Forward yield2000000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.879226400974806e+39M$20.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.879195005460081e+39M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FITSF vs JNJ ($10,000, DRIP)

YearFITSF PortfolioFITSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,676$355.77+$200.00M → FITSF
2$3,738,731,768,458$3,738,517,757,009.35$11,407$389.39+$3738731.76M → FITSF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,198$426.53+$65315062866.92M → FITSF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,056$467.62+$1066400830062625.00M → FITSF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$13,987$513.12+$16272182796453826560.00M → FITSF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$14,998$563.56+$2.3205424011366188e+23M → FITSF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$16,098$619.52+$3.0927990661046884e+27M → FITSF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,295$681.69+$3.8524105697352695e+31M → FITSF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$18,599$750.82+$4.484688260147987e+35M → FITSF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.879226400974806e+39M → FITSF

FITSF vs JNJ: Complete Analysis 2026

FITSF — Stock

Koios Beverage Corp., together with its subsidiaries, produces, markets, and sells functional beverages in the United States. The company offers nootropic supplement powder; beverage nootropic drinks under the Koios brand; functional beverages under the Fit Soda brand name; specialty ground coffee; and supplement stick packs. It distributes its products through a network of approximately 4,400 retail locations and Website. The company was formerly known as Super Nova Petroleum Corp. and changed its name to Koios Beverage Corp. in April 2018. Koios Beverage Corp. is headquartered in Denver, Colorado.

Full FITSF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this FITSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FITSF vs SCHDFITSF vs JEPIFITSF vs OFITSF vs KOFITSF vs MAINFITSF vs ABBVFITSF vs MRKFITSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.